HUE049502T2 - Policiklusos vegyületek mint bruton-tirozin-kináz inhibitorok - Google Patents

Policiklusos vegyületek mint bruton-tirozin-kináz inhibitorok

Info

Publication number
HUE049502T2
HUE049502T2 HUE16820106A HUE16820106A HUE049502T2 HU E049502 T2 HUE049502 T2 HU E049502T2 HU E16820106 A HUE16820106 A HU E16820106A HU E16820106 A HUE16820106 A HU E16820106A HU E049502 T2 HUE049502 T2 HU E049502T2
Authority
HU
Hungary
Prior art keywords
brutonium
tyrosine kinase
kinase inhibitors
polycyclic compounds
polycyclic
Prior art date
Application number
HUE16820106A
Other languages
English (en)
Hungarian (hu)
Inventor
Lun Road Cai
Wei Chen
Road Cailun
Charlotte Pooley Deckhut
James P Edwards
Brahmananda Ghosh
Kevin Kreutter
Gang Li
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Yao Wu
Kun Xiao
Feihuang Zhang
Yaoping Zhu
Nidhi Arora
Genesis M Bacani
Joseph Kent Barbay
Scott D Bembenek
Min Cai
Original Assignee
Lun Road Cai
Wei Chen
Road Cailun
Charlotte Pooley Deckhut
James P Edwards
Brahmananda Ghosh
Kevin Kreutter
Gang Li
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Yao Wu
Kun Xiao
Feihuang Zhang
Yaoping Zhu
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lun Road Cai, Wei Chen, Road Cailun, Charlotte Pooley Deckhut, James P Edwards, Brahmananda Ghosh, Kevin Kreutter, Gang Li, Mark S Tichenor, Jennifer D Venable, Jianmei Wei, John J M Wiener, Yao Wu, Kun Xiao, Feihuang Zhang, Yaoping Zhu, Janssen Pharmaceutica Nv filed Critical Lun Road Cai
Publication of HUE049502T2 publication Critical patent/HUE049502T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE16820106A 2015-12-10 2016-12-09 Policiklusos vegyületek mint bruton-tirozin-kináz inhibitorok HUE049502T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
HUE049502T2 true HUE049502T2 (hu) 2020-09-28

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16820106A HUE049502T2 (hu) 2015-12-10 2016-12-09 Policiklusos vegyületek mint bruton-tirozin-kináz inhibitorok

Country Status (30)

Country Link
US (5) US10717745B2 (enExample)
EP (2) EP3386991B1 (enExample)
JP (2) JP6835846B2 (enExample)
KR (1) KR102103395B1 (enExample)
CN (2) CN113121562B (enExample)
AR (1) AR107042A1 (enExample)
AU (1) AU2016366541B2 (enExample)
BR (1) BR112018011526B1 (enExample)
CA (1) CA3007990C (enExample)
CY (1) CY1123263T1 (enExample)
DK (1) DK3386991T3 (enExample)
EA (1) EA035168B1 (enExample)
ES (1) ES2805835T3 (enExample)
HR (1) HRP20201193T1 (enExample)
HU (1) HUE049502T2 (enExample)
IL (1) IL259863B (enExample)
JO (1) JO3794B1 (enExample)
LT (1) LT3386991T (enExample)
MA (2) MA43409B1 (enExample)
MD (1) MD3386991T2 (enExample)
ME (1) ME03803B (enExample)
MX (1) MX387590B (enExample)
PL (1) PL3386991T3 (enExample)
PT (1) PT3386991T (enExample)
RS (1) RS60604B1 (enExample)
SI (1) SI3386991T1 (enExample)
SM (1) SMT202000404T1 (enExample)
TW (1) TWI729047B (enExample)
UY (1) UY37015A (enExample)
WO (1) WO2017100662A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
US20200079790A1 (en) * 2017-03-15 2020-03-12 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
EP3802537A1 (en) 2018-06-11 2021-04-14 Amgen Inc. Kras g12c inhibitors for treating cancer
KR20210151880A (ko) 2019-04-11 2021-12-14 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피리딘 고리 함유 유도체
CN114945576B (zh) * 2020-01-07 2023-10-13 南京明德新药研发有限公司 氘代噻吩并吡啶类化合物
US20220288058A1 (en) * 2021-03-03 2022-09-15 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor
MX2023014435A (es) 2021-06-04 2024-03-08 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
MX2023015147A (es) 2021-06-30 2024-04-01 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
US11872220B2 (en) 2021-08-09 2024-01-16 Janssen Pharmaceutica Nv Methods and compositions for treating B-cell malignancies
WO2023156599A1 (en) * 2022-02-18 2023-08-24 Janssen Pharmaceutica Nv Synthesis of bruton's tyrosine kinase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
WO2006118749A1 (en) 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
AU2006278627B2 (en) 2005-08-08 2011-08-18 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
ES2616789T3 (es) 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
US8598174B2 (en) * 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2011024869A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
KR102311329B1 (ko) 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. 약제를 제조하기 위한 방법 및 중간체
MY179781A (en) * 2013-12-11 2020-11-13 Biogen Ma Inc Biaryl inhibitors of bruton's tyrosine kinase
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
US20240383914A1 (en) 2024-11-21
WO2017100662A1 (en) 2017-06-15
EA035168B1 (ru) 2020-05-08
KR20180093974A (ko) 2018-08-22
TW201734021A (zh) 2017-10-01
NZ742484A (en) 2021-09-24
UY37015A (es) 2017-06-30
CN113121562A (zh) 2021-07-16
CN108884106A (zh) 2018-11-23
US20190276471A1 (en) 2019-09-12
MX387590B (es) 2025-03-18
US12065446B2 (en) 2024-08-20
KR102103395B1 (ko) 2020-04-23
SMT202000404T1 (it) 2020-09-10
EP3386991A1 (en) 2018-10-17
PT3386991T (pt) 2020-08-18
JP2018536686A (ja) 2018-12-13
JP7072690B2 (ja) 2022-05-20
US10934310B2 (en) 2021-03-02
MX2018007075A (es) 2018-11-09
ES2805835T3 (es) 2021-02-15
ME03803B (me) 2021-04-20
SI3386991T1 (sl) 2020-08-31
MD3386991T2 (ro) 2020-11-30
MA53110A (fr) 2021-05-12
JO3794B1 (ar) 2021-01-31
BR112018011526B1 (pt) 2024-02-27
JP2021073286A (ja) 2021-05-13
EA201891378A1 (ru) 2018-12-28
EP3386991B1 (en) 2020-06-03
AR107042A1 (es) 2018-03-14
US20210101910A1 (en) 2021-04-08
HRP20201193T1 (hr) 2020-11-13
DK3386991T3 (da) 2020-07-13
CY1123263T1 (el) 2021-12-31
RS60604B1 (sr) 2020-08-31
EP3719022A1 (en) 2020-10-07
MA43409B1 (fr) 2020-10-28
US20230097422A1 (en) 2023-03-30
JP6835846B2 (ja) 2021-02-24
AU2016366541A1 (en) 2018-05-31
CA3007990A1 (en) 2017-06-15
BR112018011526A2 (pt) 2018-11-21
US20170283430A1 (en) 2017-10-05
AU2016366541B2 (en) 2021-05-13
IL259863B (en) 2020-06-30
US11319329B2 (en) 2022-05-03
TWI729047B (zh) 2021-06-01
PL3386991T3 (pl) 2021-03-08
IL259863A (en) 2018-07-31
LT3386991T (lt) 2020-08-25
CN113121562B (zh) 2022-09-13
CA3007990C (en) 2024-01-02
US10717745B2 (en) 2020-07-21

Similar Documents

Publication Publication Date Title
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
IL279258B (en) tyrosine kinase inhibitors
HUE057801T2 (hu) Aminotriazolopiridinek mint kináz inhibitorok
HUE049502T2 (hu) Policiklusos vegyületek mint bruton-tirozin-kináz inhibitorok
MA42242A (fr) Inhibiteurs de la tyrosine kinase
PL3209656T3 (pl) Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
ME03610B (me) Naftiridinska jedinjenja kao inhibitori jak kinaze
HUE042390T2 (hu) Heteroaril vegyületek kinázgátlásra
HUE043440T2 (hu) Policiklusos amidszármazékok mint CDK9 inhibitorok
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
HUE050842T2 (hu) Janus-kináz inhibitor
MA42623A (fr) Inhibiteurs de la tyrosine kinase de bruton
HUE058292T2 (hu) Aminoimidazopiridazinok mint kináz inhibitorok
EP3405192C0 (en) BRUTON'S TYROSINE KINASE INHIBITORS
IL246054B (en) Tropomyosin-related kinase (trk) inhibitors
HUE047684T2 (hu) Új szubsztituált cianoindolin származékok mint NIK inhibitorok
DK3592745T3 (da) Pyrimidopyrimidinoner anvendelige som Wee-1 kinaseinhibitorer
EP3661935A4 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES THAT MAY BE USED AS KINASE INHIBITORS
MA44607A (fr) Inhibiteurs de kinase
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors
TH1501001349A (th) โพรดรักของตัวยับยั้งอะมิโน ควินาโซลีน ไคเนส